| Year |
Citation |
Score |
| 2022 |
Wang Z, Yan H, Boysen JC, Secreto CR, Tschumper RC, Ali D, Guo Q, Zhong J, Zhou J, Gan H, Yu C, Jelinek DF, Slager SL, Parikh SA, Braggio E, et al. B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer Journal. 12: 99. PMID 35778390 DOI: 10.1038/s41408-022-00690-w |
0.418 |
|
| 2022 |
Hoelzinger DB, Quinton SJ, Walters DK, Vardam-Kaur T, Tschumper RC, Borges da Silva H, Jelinek DF. Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology. Blood Advances. 6: 3458-3471. PMID 35395072 DOI: 10.1182/bloodadvances.2021006187 |
0.3 |
|
| 2022 |
Tschumper RC, Hoelzinger DB, Walters DK, Davila JI, Osborne CA, Jelinek DF. Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells. Non-Coding Rna. 8. PMID 35202088 DOI: 10.3390/ncrna8010015 |
0.433 |
|
| 2022 |
Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, ... ... Jelinek DF, et al. Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma. Blood. PMID 35090171 DOI: 10.1182/blood.2021012811 |
0.343 |
|
| 2019 |
Walters DK, Jelinek DF. Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 22155419896802. PMID 31855110 DOI: 10.1369/0022155419896802 |
0.317 |
|
| 2019 |
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 381: 432-443. PMID 31365801 DOI: 10.1056/Nejmoa1817073 |
0.336 |
|
| 2019 |
Tschumper RC, Shanafelt TD, Kay NE, Jelinek DF. Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. Oncotarget. 10: 60-75. PMID 30713603 DOI: 10.18632/Oncotarget.26538 |
0.36 |
|
| 2019 |
Tschumper RC, Osborne CA, Chanana P, Davila JI, Walters DK, Hoelzinger DB, Jelinek DF. RNA-Seq Based Immunoglobulin Repertoire Analysis of Normal Plasma Cells Generated in an in Vitro B Cell Differentiation System Blood. 134: 1051-1051. DOI: 10.1182/Blood-2019-127327 |
0.421 |
|
| 2018 |
Hoelzinger DB, Quinton SJ, Walters DK, Tschumper RC, Jelinek DF. Proteomic and Biological Analysis of Myeloma Cell Derived Extracellular Vesicles Blood. 132: 5605-5605. DOI: 10.1182/Blood-2018-99-116926 |
0.413 |
|
| 2018 |
Walters DK, Tschumper RC, Hoelzinger DB, Quinton SJ, Shi X, Gu H, Jelinek DF. CRISPR-Mediated Loss of Immunoglobulin Heavy Chain in Multiple Myeloma Cell Line Results in Metabolic Pathway Alterations Blood. 132: 1885-1885. DOI: 10.1182/Blood-2018-99-114943 |
0.516 |
|
| 2017 |
Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, ... ... Jelinek DF, et al. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica. PMID 29269523 DOI: 10.3324/Haematol.2017.182634 |
0.352 |
|
| 2017 |
Walters DK, Arendt BK, Tschumper RC, Wu X, Jelinek DF. Characterization and use of the novel human multiple myeloma cell line MC-b11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin a heavy chain. Experimental Hematology. PMID 29030084 DOI: 10.1016/J.Exphem.2017.09.010 |
0.506 |
|
| 2017 |
Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, ... ... Jelinek DF, et al. CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED IGHV4-34 RECEPTORS: SHARED AND DISTINCT IMMUNOGENETIC FEATURES AND CLINICAL OUTCOMES. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28536306 DOI: 10.1158/1078-0432.Ccr-16-3100 |
0.424 |
|
| 2017 |
Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, ... ... Jelinek D, et al. Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study. American Journal of Hematology. PMID 28402581 DOI: 10.1002/Ajh.24762 |
0.341 |
|
| 2017 |
Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. British Journal of Haematology. PMID 28386906 DOI: 10.1111/Bjh.14647 |
0.357 |
|
| 2016 |
Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call T, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD. Association of CD49d expression with small lymphocytic lymphoma (SLL) presentation of chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 34: e19008-e19008. DOI: 10.1200/Jco.2016.34.15_Suppl.E19008 |
0.517 |
|
| 2016 |
Tschumper RC, Slager SL, Shanafelt TD, Kay NE, Jelinek DF. Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression Blood. 128: 4364-4364. DOI: 10.1182/Blood.V128.22.4364.4364 |
0.397 |
|
| 2016 |
Benard BA, Tschumper RC, Walters DK, Stephenson K, Jelinek DF, Keats JJ. Reliability of Myeloma Model Systems: KP-6 Is a Novel Hyperdiploid Cell Line Blood. 128: 3279-3279. DOI: 10.1182/Blood.V128.22.3279.3279 |
0.388 |
|
| 2015 |
Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. PMID 25931291 DOI: 10.1002/Cncr.29438 |
0.312 |
|
| 2015 |
Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, Almada LL, Elsawa SF, Knudson RA, Law ME, Ketterling RP, Cunningham JM, Wu Y, Maurer MJ, O'Byrne MM, ... ... Jelinek DF, et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma. Blood. 125: 3118-27. PMID 25833963 DOI: 10.1182/Blood-2014-05-578575 |
0.437 |
|
| 2015 |
Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, ... ... Jelinek DF, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 125: 856-9. PMID 25634617 DOI: 10.1182/Blood-2014-09-600874 |
0.41 |
|
| 2015 |
Xochelli A, Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton L, Minga E, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, ... ... Jelinek DF, et al. CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference Blood. 126: 5263-5263. DOI: 10.1182/Blood.V126.23.5263.5263 |
0.355 |
|
| 2015 |
Larsen JT, Shanafelt TD, Leis JF, LaPlant BR, Call TG, Zent CS, Hanson CA, Erlichman C, Habermann TM, Reeder CB, Bowen DA, Conte M, Boysen JC, Secreto CR, Lesnick CE, ... ... Jelinek DF, et al. Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated results from the NCCTG N1087 Alliance study Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-B02 |
0.408 |
|
| 2014 |
Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, ... ... Jelinek DF, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. The Lancet. Haematology. 1: e74-84. PMID 27030157 DOI: 10.1016/S2352-3026(14)00005-2 |
0.484 |
|
| 2014 |
Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 5: 5686-99. PMID 25015330 DOI: 10.18632/Oncotarget.2159 |
0.43 |
|
| 2014 |
Wong TW, Doyle AD, Lee JJ, Jelinek DF. Eosinophils regulate peripheral B cell numbers in both mice and humans. Journal of Immunology (Baltimore, Md. : 1950). 192: 3548-58. PMID 24616476 DOI: 10.4049/Jimmunol.1302241 |
0.55 |
|
| 2014 |
Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, et al. Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. Cancer Genetics. 207: 19-30. PMID 24613276 DOI: 10.1016/J.Cancergen.2014.01.004 |
0.31 |
|
| 2014 |
Shanafelt TD, LaPlant BR, Call TG, Nikcevich D, Leis JF, Ding W, Pettinger A, Van Dyke DL, Jelinek DF, Hanson CA, Kay NE. Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL) Blood. 124: 4673-4673. DOI: 10.1182/Blood.V124.21.4673.4673 |
0.414 |
|
| 2014 |
Ding W, Secreto C, Wu X, Braggio E, Zhang Y, Smoley SA, Shanafelt TD, Davila J, Call TG, Dyke DLV, Jelinek DF, Kay NE. CLL Mesenchymal Stromal Cells Have Decreased Replicative Potential and Senescent Phenotype: Clinical and Biologic Implications Blood. 124: 3282-3282. DOI: 10.1182/Blood.V124.21.3282.3282 |
0.453 |
|
| 2014 |
Tschumper RC, Shanafelt TD, Kay NE, Jelinek DF. Characterization of Long Non-Coding RNAs in Chronic Lymphocytic Leukemia: Evidence for Association with Disease Progression in Trisomy 12 Patients Blood. 124: 3281-3281. DOI: 10.1182/Blood.V124.21.3281.3281 |
0.436 |
|
| 2014 |
Baliakas P, Hadzidimitriou A, Sutton L, Minga E, Agathangelidis A, Tsanousa A, Scarfo L, Davis Z, Yan J, Shanafelt TD, Plevova K, Sandberg Y, Vojdeman FJ, Boudjoghra M, Tzenou T, ... ... Jelinek DF, et al. Clinical Impact of Stereotyped Antigen Receptors in Chronic Lymphocytic Leukemia Blood. 124: 3280-3280. DOI: 10.1182/Blood.V124.21.3280.3280 |
0.368 |
|
| 2014 |
Xochelli A, Kavakiotis I, Agathangelidis A, Kienle D, Davis Z, Yan XJ, Shanafelt T, Boudjogra M, Plevova K, Chatzouli M, Pedersen LB, Veronese S, Facco M, Moreno D, Chu CC, ... ... Jelinek DF, et al. Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors Blood. 124: 1969-1969. DOI: 10.1182/Blood.V124.21.1969.1969 |
0.381 |
|
| 2013 |
Walters DK, Arendt BK, Jelinek DF. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle (Georgetown, Tex.). 12: 3175-83. PMID 24013424 DOI: 10.4161/Cc.26193 |
0.456 |
|
| 2013 |
Greenberg AJ, Walters DK, Kumar SK, Vincent Rajkumar S, Jelinek DF. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. European Journal of Haematology. 91: 504-13. PMID 23992230 DOI: 10.1111/Ejh.12192 |
0.378 |
|
| 2013 |
Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 119: 3788-96. PMID 23922059 DOI: 10.1002/Cncr.28292 |
0.347 |
|
| 2013 |
Wong TW, Kita H, Hanson CA, Walters DK, Arendt BK, Jelinek DF. Induction of malignant plasma cell proliferation by eosinophils. Plos One. 8: e70554. PMID 23894671 DOI: 10.1371/Journal.Pone.0070554 |
0.432 |
|
| 2013 |
Wu X, Tschumper RC, Jelinek DF. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells. Leukemia. 27: 2264-7. PMID 23685408 DOI: 10.1038/Leu.2013.155 |
0.358 |
|
| 2013 |
Vardi A, Dagklis A, Scarfò L, Jelinek D, Newton D, Bennett F, Almeida J, Rodriguez-Caballero A, Allgood S, Lanasa M, Cortelezzi A, Orlandi E, Veronese S, Montillo M, Rawstron A, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 121: 4521-8. PMID 23596047 DOI: 10.1182/Blood-2012-12-471698 |
0.478 |
|
| 2013 |
Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 121: 4137-41. PMID 23493782 DOI: 10.1182/Blood-2012-12-470005 |
0.403 |
|
| 2013 |
Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, ... Jelinek DF, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 121: 3147-52. PMID 23422747 DOI: 10.1182/Blood-2012-07-443606 |
0.304 |
|
| 2013 |
Pei H, Wu X, Liu T, Yu K, Jelinek DF, Lou Z. The histone methyltransferase MMSET regulates class switch recombination. Journal of Immunology (Baltimore, Md. : 1950). 190: 756-63. PMID 23241889 DOI: 10.4049/Jimmunol.1201811 |
0.33 |
|
| 2013 |
Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, Leis JF, Jelinek DF, Schwager SM, Bowen DA, Hanson CA, Slager SL, Shanafelt TD. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 27: 136-41. PMID 22781591 DOI: 10.1038/Leu.2012.187 |
0.353 |
|
| 2013 |
Parikh SA, Sharma RG, Call TG, Habermann TM, Ding W, Leis JF, Schwager S, Hanson CA, Macon WR, Tschumper RC, Jelinek DF, Kay NE, Slager SL, Rabe KG, Shanafelt TD. Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome Blood. 122: 4179-4179. DOI: 10.1182/Blood.V122.21.4179.4179 |
0.341 |
|
| 2013 |
Parikh SA, Shanafelt TD, Rabe KG, Ding W, Call TG, Schwager S, Jelinek DF, Kay NE, Slager SL, Leis J. Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes Blood. 122: 4178-4178. DOI: 10.1182/Blood.V122.21.4178.4178 |
0.341 |
|
| 2013 |
Ding W, Shanafelt TD, Zent CS, Leis JF, LaPlant BR, Call TG, Hanson CA, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte MJ, Boysen J, Secreto C, ... ... Jelinek DF, et al. The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) Blood. 122: 2882-2882. DOI: 10.1182/Blood.V122.21.2882.2882 |
0.342 |
|
| 2013 |
Greenberg AJ, Walters DK, Arendt BK, Tschumper RC, Kumar SK, Rajkumar SV, Jelinek DF. Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression Levels Blood. 122: 1962-1962. DOI: 10.1182/Blood.V122.21.1962.1962 |
0.385 |
|
| 2013 |
Yellapantula VD, Allen K, Jelinek DF, Bergsagel L, Keats JJ. The Comprehensive Genomic Characterization Of All Commercially and Non-Commercially Available Multiple Myeloma Cell Lines Blood. 122: 1914-1914. DOI: 10.1182/Blood.V122.21.1914.1914 |
0.339 |
|
| 2012 |
Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2483-91. PMID 22564988 DOI: 10.1200/Jco.2011.39.3090 |
0.354 |
|
| 2012 |
Tschumper RC, Asmann YW, Hossain A, Huddleston PM, Wu X, Dispenzieri A, Eckloff BW, Jelinek DF. Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. Oncotarget. 3: 502-13. PMID 22522905 DOI: 10.18632/Oncotarget.469 |
0.345 |
|
| 2012 |
Arendt BK, Walters DK, Wu X, Tschumper RC, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia. 26: 2286-96. PMID 22460757 DOI: 10.1038/Leu.2012.91 |
0.387 |
|
| 2012 |
Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia. 26: 1698-701. PMID 22261920 DOI: 10.1038/Leu.2012.14 |
0.305 |
|
| 2012 |
Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, Leis JF, Jelinek DF, Slager SL, Hanson CA. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia. 26: 373-6. PMID 21836611 DOI: 10.1038/Leu.2011.211 |
0.411 |
|
| 2012 |
Tschumper RC, Dispenzieri A, Abraham RS, Henderson KJ, Jelinek DF. Molecular Interrogation of Biclonal Multiple Myeloma for Clonal Relatedness. Blood. 120: 2928-2928. DOI: 10.1182/Blood.V120.21.2928.2928 |
0.399 |
|
| 2012 |
Wong TW, Walters DK, Kita H, Jelinek DF. Eosinophils in the Bone Marrow Microenvironment: Effects On Malignant Plasma Cell Biology. Blood. 120: 2917-2917. DOI: 10.1182/Blood.V120.21.2917.2917 |
0.452 |
|
| 2012 |
Parikh SA, Rabe KG, Kay NE, Zent CS, Call TG, Ding W, Hanson CA, Macon WR, Schwager S, Jelinek DF, Slager SL, Shanafelt TD. Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's Syndrome): Large Retrospective Analysis From a Single Institution. Blood. 120: 2902-2902. DOI: 10.1182/Blood.V120.21.2902.2902 |
0.323 |
|
| 2012 |
Vardi A, Dagklis A, Scarfò L, Jelinek DF, Newton DJ, Doughty C, Almeida J, Rodriguez-Caballero A, Allgood SD, Lanasa MC, Cortelezzi A, Orlandi EM, Veronese S, Montillo M, Rawstron A, et al. What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not. Blood. 120: 2883-2883. DOI: 10.1182/Blood.V120.21.2883.2883 |
0.415 |
|
| 2011 |
Gutierrez A, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF. Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression. Plos One. 6: e26056. PMID 21998751 DOI: 10.1371/Journal.Pone.0026056 |
0.801 |
|
| 2011 |
Chen CY, Senac JS, Weaver EA, May SM, Jelinek DF, Greipp P, Witzig T, Barry MA. Species D adenoviruses as oncolytics against B-cell cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6712-22. PMID 21890454 DOI: 10.1158/1078-0432.Ccr-11-0968 |
0.449 |
|
| 2011 |
Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. British Journal of Haematology. 155: 53-64. PMID 21749361 DOI: 10.1111/J.1365-2141.2011.08794.X |
0.473 |
|
| 2011 |
Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia. 25: 1344-53. PMID 21566653 DOI: 10.1038/Leu.2011.94 |
0.345 |
|
| 2011 |
Wu X, Smoley SA, Peterson MA, Walters DK, Arendt BK, Nowakowski GS, Van Dyke DL, Kay NE, Jelinek DF. Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells. British Journal of Haematology. 153: 402-5. PMID 21323871 DOI: 10.1111/J.1365-2141.2010.08514.X |
0.532 |
|
| 2011 |
Wu X, Pei H, Liu T, Yu K, Jelinek DF, Lou Z. The Histone Methytransferase MMSET Regulates Class-Switch Recombination Blood. 118: 691-691. DOI: 10.1182/Blood.V118.21.691.691 |
0.404 |
|
| 2011 |
Arendt BK, Walters DK, Wu X, Tschumper RC, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. CD147 Is a Novel Regulator of Progression and Proliferation of Multiple Myeloma Plasma Cells Blood. 118: 470-470. DOI: 10.1182/Blood.V118.21.470.470 |
0.408 |
|
| 2011 |
Shanafelt TD, Tun H, Hanson CA, Zent CS, Leis JF, Call TG, LaPlant BR, Bowen D, Pavey ES, Jelinek DF, Kay N. Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL, Blood. 118: 3899-3899. DOI: 10.1182/Blood.V118.21.3899.3899 |
0.324 |
|
| 2011 |
Shanafelt TD, Lanasa MC, Zent CS, Leis JF, Call TG, LaPlant BR, Tun H, Bowen DA, Jelinek DF, Hanson CA, Kay N. Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL, Blood. 118: 3898-3898. DOI: 10.1182/Blood.V118.21.3898.3898 |
0.331 |
|
| 2011 |
Braggio E, Kay N, Van Wier S, Tschumper RC, Smoley SA, Eckel-Passow JE, Sassoon T, Dyke DLV, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse Blood. 118: 2838-2838. DOI: 10.1182/Blood.V118.21.2838.2838 |
0.344 |
|
| 2011 |
Tschumper RC, Asmann YW, Hossain A, Huddleston PM, Wu X, Dispenzieri A, Eckloff BW, Jelinek DF. Assessment of Multiple Myeloma IGHV Intraclonal Variation by Massively Parallel Pyrosequencing Blood. 118: 1814-1814. DOI: 10.1182/Blood.V118.21.1814.1814 |
0.352 |
|
| 2011 |
Shanafelt T, Lanasa M, Zent C C, Leis J, Call T, LaPlant B B, Tun H, Bowen D, Jelinek D, Hanson C C, Kay N. 5.12 Ofatumumab-Based Chemoimmunotherapy for Patients With Previously Untreated Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma and Leukemia. 11: S250. DOI: 10.1016/J.Clml.2011.09.166 |
0.331 |
|
| 2011 |
Shanafelt T, Tun H, Hanson C, Zent C, Leis J, Call T, LaPlant B, Bowen D, Pavey E, Jelinek D, Kay N. 5.11 Lenalidomide Consolidation Seems to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma and Leukemia. 11: S249. DOI: 10.1016/J.Clml.2011.09.165 |
0.326 |
|
| 2010 |
Wu X, Tschumper RC, Gutierrez A, Mihalcik SA, Nowakowski GS, Jelinek DF. Selective induction of DNA repair pathways in human B cells activated by CD4+ T cells. Plos One. 5: e15549. PMID 21179576 DOI: 10.1371/Journal.Pone.0015549 |
0.811 |
|
| 2010 |
Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genetics and Cytogenetics. 203: 161-8. PMID 21156228 DOI: 10.1182/Blood.V116.21.2406.2406 |
0.322 |
|
| 2010 |
Mihalcik SA, Tschumper RC, Jelinek DF. Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle (Georgetown, Tex.). 9: 4884-92. PMID 21099364 DOI: 10.4161/Cc.9.24.14156 |
0.821 |
|
| 2010 |
Dingli D, Arendt BK, Bajzer Z, Jelinek DF. Evolutionary dynamics of two related malignant plasma cell lines. Cell Cycle (Georgetown, Tex.). 9: 3792-7. PMID 20890105 DOI: 10.4161/Cc.9.18.13047 |
0.376 |
|
| 2010 |
Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 116: 2984-93. PMID 20606160 DOI: 10.1182/Blood-2010-02-269894 |
0.385 |
|
| 2010 |
Gutierrez A, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM, Slager SL, Kay NE, Jelinek DF. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 116: 2975-83. PMID 20595513 DOI: 10.1182/Blood-2010-02-269878 |
0.794 |
|
| 2010 |
Mihalcik SA, Huddleston PM, Wu X, Jelinek DF. The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation. Journal of Immunology (Baltimore, Md. : 1950). 185: 1045-54. PMID 20554963 DOI: 10.4049/Jimmunol.1001120 |
0.822 |
|
| 2010 |
Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. Erratum: VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: Implication for apoptosis resistance (Leukemia (2005) 19 (513-523) doi:10.1038/sj.leu.2403667) Leukemia. 24. PMID 20389304 DOI: 10.1038/Leu.2010.28 |
0.423 |
|
| 2010 |
Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer. 116: 2180-7. PMID 20187101 DOI: 10.1002/Cncr.25028 |
0.363 |
|
| 2010 |
Mihalcik SA, Huddleston PM, Wu X, Jelinek DF. Correction: The Structure of the TNFRSF13C Promoter Enables Differential Expression of BAFF-R during B Cell Ontogeny and Terminal Differentiation The Journal of Immunology. 185: 6384-6384. DOI: 10.4049/Jimmunol.1090102 |
0.807 |
|
| 2010 |
Shanafelt T, Kay NE, Rabe K, Call T, Zent CS, Schwager S, Leis J, Jelinek DF, Slager S, Hanson C. Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population Blood. 116: 700-700. DOI: 10.1182/Blood.V116.21.700.700 |
0.46 |
|
| 2010 |
Braggio E, Kay NE, Wier SV, Smoley S, Eckel-Passow J, Sassoon T, Dyke DLV, Jelinek DF, Shanafelt T, Tschumper R, Barrett M, Kipps TJ, Byrd JC, Fonseca R. Longitudinal Genomic Analyses In Chronic Lymphocytic Leukemia (CLL) Patients Reveal Clonal Relationship and Genomic Evolution In Disease Progression and After Therapy Blood. 116: 3605-3605. DOI: 10.1182/Blood.V116.21.3605.3605 |
0.403 |
|
| 2010 |
Mraz M, Zent CS, Church AK, Baig NA, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Witzig TE, Nowakowski GS. Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target Blood. 116: 3115-3115. DOI: 10.1182/Blood.V116.21.3115.3115 |
0.526 |
|
| 2010 |
Kay NE, Kim H, Kempin S, Rosen ST, Lazarus H, Jelinek DF, Tallman MS. Predictors of Response to Salvage Therapy for Advanced Chronic Lymphocytic Leukemia (ECOG Protocol 2903) Blood. 116: 2463-2463. DOI: 10.1182/Blood.V116.21.2463.2463 |
0.361 |
|
| 2010 |
Shanafelt T, Tun H, Hanson C, Zent CS, Leis J, Call T, LaPlant B, Bowen D, Laumann K, Jelinek DF, Kay NE. Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL Blood. 116: 1379-1379. DOI: 10.1182/Blood.V116.21.1379.1379 |
0.335 |
|
| 2009 |
Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leukemia & Lymphoma. 50: 1261-8. PMID 19811329 DOI: 10.1080/10428190903026492 |
0.385 |
|
| 2009 |
Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, Jenkins G, Jelinek DF, Morice WG, Boysen J, Schwager S, Bowen D, Slager SL, Hanson CA. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3959-63. PMID 19620484 DOI: 10.1200/Jco.2008.21.2704 |
0.458 |
|
| 2009 |
Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD, Kurihara N. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood. 113: 4894-902. PMID 19282458 DOI: 10.1182/Blood-2008-08-173948 |
0.409 |
|
| 2009 |
Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1844-9. PMID 19255329 DOI: 10.1200/Jco.2008.17.0795 |
0.439 |
|
| 2009 |
Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 115: 363-72. PMID 19090008 DOI: 10.1002/Cncr.24004 |
0.313 |
|
| 2009 |
Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, Morice WG, Boysen J, Zakko L, Schwager S, Slager SL, Hanson CA. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood. 113: 4188-96. PMID 19015397 DOI: 10.1182/Blood-2008-09-176149 |
0.532 |
|
| 2009 |
Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood. 113: 535-7. PMID 19008456 DOI: 10.1182/Blood-2008-08-173450 |
0.417 |
|
| 2009 |
Wu X, Tschumper RC, Gutierrez A, Mihalcik SA, Nowakowski GS, Capello D, Jelinek DF. Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells. Blood. 114: 92-92. DOI: 10.1182/Blood.V114.22.92.92 |
0.812 |
|
| 2009 |
Gutierrez A, Tschumper R, Shanafelt TD, Eckel-Passow J, Kay NE, Jelinek DF. Aberrant Regulation of the LEF-1 Locus in Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL): A Possible Role for Epigenetic Regulation. Blood. 114: 669-669. DOI: 10.1182/Blood.V114.22.669.669 |
0.797 |
|
| 2009 |
Kay NE, Kim HT, Volinia S, Croce CM, Jelinek DF, Kempin S, Tallman MS. MicroRNA Expression Profiling of CLL B Cells From Relapsed/Refractory CLL Patients Reveals a Signature Group of Genes That Are Associated with Clinical Responses: Results of An ECOG Trial E2903. Blood. 114: 4377-4377. DOI: 10.1182/Blood.V114.22.4377.4377 |
0.368 |
|
| 2009 |
Walters DK, Tschumper RC, Wu X, Henderson KJ, Dispenzieri A, Jelinek DF. Evidence for Ongoing DNA Damage in Multiple Myeloma as Revealed by Constitutive Phosphorylation of H2AX. Blood. 114: 2817-2817. DOI: 10.1182/Blood.V114.22.2817.2817 |
0.437 |
|
| 2009 |
Mihalcik SA, Jelinek DF. C-Rel in the Regulation of BAFF-R Expression in Malignant Human B Cells. Blood. 114: 2400-2400. DOI: 10.1182/Blood.V114.22.2400.2400 |
0.83 |
|
| 2009 |
Leis JF, Braggio E, Van Wier S, Keats JJ, Jelinek DF, van Dyke D, Zent CS, Shanafelt TD, Call TG, Kay NE, Fonseca R. Impact of IgVH Gene Mutational Status and VH Family Usage on Chromosomal Aberrations Detected by High-Resolution Array-CGH in B-CLL. Blood. 114: 1246-1246. DOI: 10.1182/Blood.V114.22.1246.1246 |
0.358 |
|
| 2009 |
Wu X, Jelinek DF. Response: Cautious interpretation of assessment of AID variant activities using cells with endogenous AID expression Blood. 113: 1864-1864. DOI: 10.1182/Blood-2008-11-187732 |
0.335 |
|
| 2008 |
Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 113: 2110-8. PMID 18759253 DOI: 10.1002/Cncr.23824 |
0.303 |
|
| 2008 |
Wu X, Darce JR, Chang SK, Nowakowski GS, Jelinek DF. Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells. Blood. 112: 4675-82. PMID 18684869 DOI: 10.1182/Blood-2008-03-145995 |
0.548 |
|
| 2008 |
Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leukemia Research. 32: 1849-56. PMID 18584865 DOI: 10.1016/J.Leukres.2008.05.014 |
0.423 |
|
| 2008 |
Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM, Tschumper RC, Wu X, Zeldenrust SR, Jelinek DF. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 112: 1931-41. PMID 18567838 DOI: 10.1182/Blood-2008-03-143040 |
0.373 |
|
| 2008 |
Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. Journal of Immunology (Baltimore, Md. : 1950). 180: 7394-403. PMID 18490739 DOI: 10.4049/Jimmunol.180.11.7394 |
0.796 |
|
| 2008 |
Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, Jelinek DF, Kay NE. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: e5-6. PMID 18467710 DOI: 10.1200/Jco.2008.16.7874 |
0.415 |
|
| 2008 |
Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. British Journal of Haematology. 141: 607-14. PMID 18384436 DOI: 10.1111/j.1365-2141.2008.07070.x |
0.408 |
|
| 2008 |
Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. British Journal of Haematology. 141: 615-21. PMID 18373706 DOI: 10.1111/J.1365-2141.2008.07086.X |
0.35 |
|
| 2008 |
Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. British Journal of Haematology. 140: 537-46. PMID 18275431 DOI: 10.1111/J.1365-2141.2007.06965.X |
0.515 |
|
| 2008 |
Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, Morice WG, Hanson CA. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? Leukemia Research. 32: 1458-61. PMID 18179821 DOI: 10.1016/J.Leukres.2007.11.030 |
0.443 |
|
| 2008 |
Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. The Journal of Clinical Investigation. 118: 306-15. PMID 18064298 DOI: 10.1172/Jci32625 |
0.453 |
|
| 2008 |
Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 111: 785-9. PMID 17942755 DOI: 10.1182/Blood-2007-08-108357 |
0.303 |
|
| 2008 |
Gutierrez A, Tschumper R, Eckel-Passow J, Kay NE, Jelinek DF. Overexpression of the LEF-1 and TCF4 Transcription Factors in B-CLL: Further Evidence for a Role of the Wnt Signaling Pathway in B-CLL Biology and Leukemogenesis Blood. 112: 544-544. DOI: 10.1182/Blood.V112.11.544.544 |
0.8 |
|
| 2008 |
Mihalcik SA, Tschumper RC, Jelinek DF. Molecular Mechanisms Regulating BAFF and APRIL Receptor Expression in B Cells: Promoter Structure and Epigenetics Blood. 112: 4765-4765. DOI: 10.1182/Blood.V112.11.4765.4765 |
0.838 |
|
| 2008 |
Nowakowski GS, Wu X, Abrahamzon JL, Tschumper R, Kay NE, Jelinek DF. ABCG2 Is Expressed in a Small Population of Circulating CLL B-Cells Characterized by Expression of Self-Renewal and Early B-Cell Development Genes and Resistance to Therapy Blood. 112: 3156-3156. DOI: 10.1182/Blood.V112.11.3156.3156 |
0.551 |
|
| 2008 |
Wu X, Nowakowski GS, Smoley SA, Arendt BA, Peterson MA, van Dyke D, Kay NE, Jelinek DF. Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis Blood. 112: 3124-3124. DOI: 10.1182/Blood.V112.11.3124.3124 |
0.529 |
|
| 2008 |
Keats JJ, Arendt BK, Braggio E, Barrett M, Price-Troska T, Fonseca R, Bergsagel PL, Jelinek DF. Comparison of Multiple Myeloma Donor Patient Samples and Derived Cell Lines Identifies a Confirmed Hyperdiploid Myeloma Cell Line and Demonstrates Remarkable Genetic Similarity Between Cell Lines and Patient Samples Blood. 112: 2732-2732. DOI: 10.1182/Blood.V112.11.2732.2732 |
0.401 |
|
| 2008 |
Awan F, Kay NE, Davis M, Wu W, Leung N, Jelinek DF, Tschumper R, Secreto C, Lin TS, Grever MR, Shanafelt T, Zent CS, Call TG, Heerema NA, Lozanski G, et al. Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab. Blood. 112: 2105-2105. DOI: 10.1182/blood.v112.11.2105.2105 |
0.33 |
|
| 2008 |
Shanafelt T, Kay NE, Rabe K, Call TG, Zent CS, Maddocks K, Jelinek DF, Boysen J, Bowen D, Schwager S, Jenkins G, Slager SL, Hanson CA. Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic. Blood. 112: 2063-2063. DOI: 10.1182/Blood.V112.11.2063.2063 |
0.461 |
|
| 2008 |
Arendt BK, Wu X, Greipp PR, Rajkumar SV, Kyle R, Ketterling RP, Knudson RA, Jelinek DF. Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control. Blood. 112: 1707-1707. DOI: 10.1182/Blood.V112.11.1707.1707 |
0.459 |
|
| 2007 |
Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leukemia & Lymphoma. 48: 2412-7. PMID 18067017 DOI: 10.1080/10428190701724801 |
0.352 |
|
| 2007 |
Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. Journal of Immunology (Baltimore, Md. : 1950). 179: 7276-86. PMID 18025170 DOI: 10.4049/Jimmunol.179.11.7276 |
0.575 |
|
| 2007 |
Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 139: 398-404. PMID 17910629 DOI: 10.1111/J.1365-2141.2007.06801.X |
0.378 |
|
| 2007 |
Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, et al. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research. 31: 1737-40. PMID 17659340 DOI: 10.1016/J.LEUKRES.2007.05.020 |
0.426 |
|
| 2007 |
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine. 356: 2582-90. PMID 17582068 DOI: 10.1056/Nejmoa070389 |
0.319 |
|
| 2007 |
Darce JR, Arendt BK, Chang SK, Jelinek DF. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. Journal of Immunology (Baltimore, Md. : 1950). 178: 5612-22. PMID 17442944 DOI: 10.4049/Jimmunol.178.9.5612 |
0.537 |
|
| 2007 |
Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clinic Proceedings. 82: 449-53. PMID 17418074 DOI: 10.4065/82.4.449 |
0.488 |
|
| 2007 |
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 799-804. PMID 17283363 DOI: 10.1200/Jco.2006.08.3089 |
0.346 |
|
| 2007 |
Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 21: 169-74. PMID 17051241 DOI: 10.1038/Sj.Leu.2404445 |
0.445 |
|
| 2007 |
Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 109: 405-11. PMID 17008537 DOI: 10.1182/Blood-2006-07-033274 |
0.37 |
|
| 2007 |
Maddocks-Christianson K, Hanson CA, Jenkins G, Zent CS, Slager SL, Call TG, Bowen D, Tschumper R, Jelinek DF, Kay NE, Shanafelt TD. Molecular Prognostic Factors and Outcome among a Cohort of Patients with Monoclonal B-Cell Lymphocytosis (MBL). Blood. 110: 748-748. DOI: 10.1182/Blood.V110.11.748.748 |
0.451 |
|
| 2007 |
Zent CS, Ding W, Giordano KF, Schwager SM, Shanafelt TD, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Kay NE, Slager SL. The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). Blood. 110: 746-746. DOI: 10.1182/Blood.V110.11.746.746 |
0.336 |
|
| 2007 |
Nowakowski GS, Hoyer JD, Shanafelt TD, Jelinek DF, Rassenti LZ, Kipps TJ, Kay NE. Percentage of Smudge Cells on Blood Smear Predicts Prognosis in Chronic Lymphocytic Leukemia: A Multicenter Study. Blood. 110: 745-745. DOI: 10.1182/BLOOD.V110.11.745.745 |
0.392 |
|
| 2007 |
Kempin S, Kay N, Sun Z, Secreto C, Tschumper R, Jelinek D, Smoley S, Van Dyke D, Saltzman J, Rosen S, Tallman M. Early Results of Pentostatin, Cytoxan, Rituximab (PCR) Followed by CAMPATH-H (CA) for the Treatment of Relapse/Refractory Chronic Lymphocytic Leukemia (CLL) in ECOG Protocol E2903. Blood. 110: 3109-3109. DOI: 10.1182/Blood.V110.11.3109.3109 |
0.364 |
|
| 2007 |
Van Dyke DL, Dewald G, Call T, Jelinek D, Zent C, Shanafelt T, Smoley S, Stockero K, Kay N. Deletion 13q in B-CLL: Interphase FISH Reveals More 13q- Than Does CpG Stimulation. Blood. 110: 2070-2070. DOI: 10.1182/Blood.V110.11.2070.2070 |
0.324 |
|
| 2007 |
Nowakowski GS, Smoley S, Schwager S, Zent CS, Call TG, Shanafelt TD, Hanson CA, Tschumper RC, Jelinek DF, Dyke DLV, Kay NE. Presence of Immunoglobulin Heavy Chain Gene (IGH) Translocations in Chronic Lymphocytic Leukemia Is Related to Poor Prognosis. Blood. 110: 2067-2067. DOI: 10.1182/Blood.V110.11.2067.2067 |
0.391 |
|
| 2007 |
Zent CS, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Secreto CR, Bowen DA, Geyer SM, Kabat BF, LaPlant BR, Wu W, Kay NE. Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL). Blood. 110: 2050-2050. DOI: 10.1182/Blood.V110.11.2050.2050 |
0.346 |
|
| 2007 |
Shanafelt T, Kaufmann S, Call T, Zent CS, Wu W, Bowen D, Secreto C, Ghosh A, Kabat B, Yang C, Jelinek D, Erlichman C, Kay NE. A Phase 1 Trial of Daily Oral Green Tea Extract in Asymptomatic, Rai Stage 0–II Patients with Chronic Lymphocytic Leukemia. Blood. 110: 2047-2047. DOI: 10.1182/Blood.V110.11.2047.2047 |
0.32 |
|
| 2007 |
Dispenzieri A, Kyle RA, Katzmann JA, Larson D, Benson J, Clark R, Melton LJ, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma. Blood. 110: 1487-1487. DOI: 10.1182/Blood.V110.11.1487.1487 |
0.342 |
|
| 2007 |
Tschumper RC, Darce JR, Wu X, Mihalcik SA, Jelinek DF. Comprehensive Analysis of BAFF Binding Receptor Profiles and Receptor Occupancy in B Cell Chronic Lymphocytic Leukemia: Identification of Discrete Phenotypic Subgroups. Blood. 110: 1135-1135. DOI: 10.1182/Blood.V110.11.1135.1135 |
0.84 |
|
| 2006 |
Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4634-41. PMID 17008705 DOI: 10.1200/Jco.2006.06.9492 |
0.337 |
|
| 2006 |
Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF. A role for BLyS in the activation of innate immune cells. Blood. 108: 2687-94. PMID 16825497 DOI: 10.1182/Blood-2005-12-017319 |
0.471 |
|
| 2006 |
Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 108: 2755-63. PMID 16804116 DOI: 10.1182/Blood-2006-02-005488 |
0.521 |
|
| 2006 |
Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 983-7. PMID 16432079 DOI: 10.1200/Jco.2005.02.7938 |
0.451 |
|
| 2006 |
Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia. 19: 2264-72. PMID 16208411 DOI: 10.1038/Sj.Leu.2403975 |
0.472 |
|
| 2006 |
Wu X, Brown BL, Darce JR, Arendt BK, Chang S, Tschumper RC, Kay NE, Jelinek DF. Expression and Functional Analysis of Activation-Induced Deaminase (AID) in Normal Human B Lymphocytes. Blood. 108: 934-934. DOI: 10.1182/Blood.V108.11.934.934 |
0.557 |
|
| 2006 |
Arendt BK, Ahmann GJ, Mulvihill EM, Sikkink LA, Dispenzieri A, Ramirez-Alvarado M, Zeldenrust SR, Fonseca R, Jelinek DF. Establishment and Characterization of an Ig Lambda Secreting Cell Line from a Patient with AL Amyloidosis. Blood. 108: 3520-3520. DOI: 10.1182/Blood.V108.11.3520.3520 |
0.424 |
|
| 2006 |
Zent CS, Bone ND, Call TG, Shanafelt TD, Geyer SM, Secreto CR, Jelinek DF, Dewald GW, Kay NE. Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis. Blood. 108: 2829-2829. DOI: 10.1182/Blood.V108.11.2829.2829 |
0.342 |
|
| 2006 |
Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant B, Call TG, Jelinek DF, Zent CS, Kay NE. Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. Blood. 108: 2785-2785. DOI: 10.1182/Blood.V108.11.2785.2785 |
0.484 |
|
| 2006 |
Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Call TG, Jelinek DF. D Gene Usage Predicts Clinical Outcome in Patients with Low Rai Risk Unmutated B-CLL. Blood. 108: 2779-2779. DOI: 10.1182/Blood.V108.11.2779.2779 |
0.405 |
|
| 2006 |
Maddocks-Christianson K, Zent CS, Slager S, Schwager S, Reinalda M, Call TG, Bowen D, Hoyer J, Jelinek DF, Kay NE, Shanafelt TD. Prior Treatment Relates More Strongly to Richter’s Transformation Than ZAP-70, CD38, IgVH Gene Mutation Status, and Cytogenetic Abnormalities: Findings of an Observational Cohort Study of 962 Patients with CLL. Blood. 108: 2777-2777. DOI: 10.1182/Blood.V108.11.2777.2777 |
0.398 |
|
| 2006 |
Shanafelt TD, Bone ND, Geyer SM, LaPlant B, Witzig TE, Schwager S, Dewald GW, Nowakowski GS, Tschumper RC, Zent CS, Call TG, Jelinek DF, Kay NE. Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia. Blood. 108: 2776-2776. DOI: 10.1182/Blood.V108.11.2776.2776 |
0.505 |
|
| 2006 |
Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. Reply to ‘CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance’ by Zucchetto et al. Leukemia. 20: 528-528. DOI: 10.1038/Sj.Leu.2404088 |
0.42 |
|
| 2005 |
Wu X, Jelinek DF. A-Miz-ing BCL6. Nature Immunology. 6: 964-6. PMID 16177801 DOI: 10.1038/Ni1005-964 |
0.386 |
|
| 2005 |
Barnidge DR, Jelinek DF, Muddiman DC, Kay NE. Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents. Journal of Proteome Research. 4: 1310-7. PMID 16083281 DOI: 10.1021/Pr050028F |
0.379 |
|
| 2005 |
Kay NE, Bone ND, Lee YK, Jelinek DF, Leland P, Battle TE, Frank DA, Puri RK. A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leukemia Research. 29: 1009-18. PMID 16038727 DOI: 10.1016/J.Leukres.2004.11.025 |
0.408 |
|
| 2005 |
Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia. 19: 1018-24. PMID 15800671 DOI: 10.1038/Sj.Leu.2403726 |
0.552 |
|
| 2005 |
Barnidge DR, Tschumper RC, Jelinek DF, Muddiman DC, Kay NE. Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 819: 33-9. PMID 15797518 DOI: 10.1016/J.Jchromb.2005.01.021 |
0.343 |
|
| 2005 |
Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology. 33: 272-8. PMID 15730850 DOI: 10.1016/J.Exphem.2004.11.015 |
0.309 |
|
| 2005 |
Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 19: 513-23. PMID 15703780 DOI: 10.1038/Sj.Leu.2403667 |
0.419 |
|
| 2005 |
Fink SR, Paternoster SF, Smoley SA, Flynn HC, Geyer SM, Shanafelt TD, Lee YK, Jelinek DF, Kay NE, Dewald GW. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia Leukemia Research. 29: 253-262. PMID 15661260 DOI: 10.1016/J.Leukres.2004.07.012 |
0.389 |
|
| 2005 |
Jelinek DF, Darce JR. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Current Directions in Autoimmunity. 8: 266-88. PMID 15564725 DOI: 10.1159/000082107 |
0.501 |
|
| 2005 |
Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. The Journal of Pharmacology and Experimental Therapeutics. 312: 537-45. PMID 15388785 DOI: 10.1124/Jpet.104.074815 |
0.375 |
|
| 2005 |
Nowakowski GS, Lee YK, Bone ND, Morice WG, Barnidge D, Jelinek DF, Tschumper R, Shanafelt TD, Zent CS, Rassenti LZ, Kipps TJ, Kay NE. Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease. Blood. 106: 707-707. DOI: 10.1182/Blood.V106.11.707.707 |
0.451 |
|
| 2005 |
Masri AA, Tschumper R, Van Wier S, Price-Troska T, Jelinek DF, Fonseca R. Functional Analysis of p53 in the JMW Myeloma Cell Line. Blood. 106: 5112-5112. DOI: 10.1182/Blood.V106.11.5112.5112 |
0.435 |
|
| 2005 |
Tschumper RC, Geyer SM, Shanafelt TD, Kay NE, Mulvihill EM, Jelinek DF. Molecular and Clinical Analysis of a Midwest Cohort of B-CLL Patients Utilizing the Immunoglobulin VH 1-69 Gene. Blood. 106: 5016-5016. DOI: 10.1182/Blood.V106.11.5016.5016 |
0.425 |
|
| 2005 |
Masri AA, Tschumper R, Van Wier S, Price-Troska T, Jelinek D, Fonseca R. The “Trans-Amplicon” in Myeloma; a Mechanism of Clonal Selection Favoring Retention of Derivative Chromosomes Involved in Translocations. Blood. 106: 4346-4346. DOI: 10.1182/Blood.V106.11.4346.4346 |
0.428 |
|
| 2004 |
Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 104: 2247-53. PMID 15251985 DOI: 10.1182/Blood-2004-02-0762 |
0.52 |
|
| 2004 |
Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 104: 788-94. PMID 14996703 DOI: 10.1182/Blood-2003-08-2763 |
0.462 |
|
| 2004 |
Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A. Inihibitor of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma Leukemia. 18: 616-623. PMID 14749704 DOI: 10.1038/Sj.Leu.2403281 |
0.378 |
|
| 2004 |
Walters DK, Jelinek DF. A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells. Oncogene. 23: 1197-205. PMID 14647450 DOI: 10.1038/Sj.Onc.1207203 |
0.321 |
|
| 2004 |
Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 103: 2308-15. PMID 14615378 DOI: 10.1182/Blood-2003-06-1992 |
0.386 |
|
| 2004 |
Pittner BT, Jelinek DF, Kay NE. CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL. Leukemia. 18: 180-2. PMID 14523466 DOI: 10.1038/Sj.Leu.2403151 |
0.459 |
|
| 2004 |
Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103: 689-94. PMID 14512299 DOI: 10.1182/Blood-2003-06-2043 |
0.553 |
|
| 2004 |
Ansell SM, Geyer SM, Witzig TE, Jelinek DF, Kurtin PJ, Micallef INM, Stella P, Etzell P, Erlichman C, Novak AJ. NCCTG trial of concomitant or sequential IL-12 in combination with rituximab in previously treated non-Hodgkin lymphoma patients Journal of Clinical Oncology. 22: 6591-6591. DOI: 10.1200/Jco.2004.22.14_Suppl.6591 |
0.429 |
|
| 2004 |
Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Tait S, Call T, Kay NE, Jelinek DF, Cerhan JR, Ansell SM. Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms. Blood. 104: 964-964. DOI: 10.1182/Blood.V104.11.964.964 |
0.4 |
|
| 2004 |
Pittner BT, Tschumper RC, Morlan BW, Ballman KV, Kay NE, Jelinek DF. Leukemic B Cells from CD38 Positive but Not CD38 Negative B-CLL Patients Express Heightened Levels of Cell Cycle Related Genes. Blood. 104: 4809-4809. DOI: 10.1182/Blood.V104.11.4809.4809 |
0.519 |
|
| 2004 |
Naumovski L, Bone ND, Sirisawad M, Miller R, Jelinek DF, Tschumper RC, Kay NE. Motexafin Gadolinium, a Redox Mediator, Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells and Is Additive or Synergistic with Fludarabine. Blood. 104: 4799-4799. DOI: 10.1182/Blood.V104.11.4799.4799 |
0.472 |
|
| 2004 |
Kay NE, Geyer SM, Lin T, Call TG, Jelinek DF, Bone ND, Dewald GW, Heerema NL, Tschumper R, Smith L, Grever MR, Byrd JC. Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia. Blood. 104: 339-339. DOI: 10.1182/Blood.V104.11.339.339 |
0.424 |
|
| 2004 |
Tschumper RC, Nolz JC, Kay NE, Jankiewicz CA, Jelinek DF. ZAP-70 Expression Associated with Activation in Normal Human B Cells and B Cell Chronic Lymphocytic Leukemia. Blood. 104: 2794-2794. DOI: 10.1182/Blood.V104.11.2794.2794 |
0.574 |
|
| 2004 |
Arendt BK, Fonseca R, Ahmann G, Jelinek DF. Analysis of Intratumor Heterogeneity in Multiple Myeloma Using Methylcellulose Clonogenic Assays. Blood. 104: 2346-2346. DOI: 10.1182/Blood.V104.11.2346.2346 |
0.447 |
|
| 2004 |
Chang SK, Jelinek DF. BLyS Regulates Human Myeloma Cell IL-6 Expression. Blood. 104: 1412-1412. DOI: 10.1182/Blood.V104.11.1412.1412 |
0.431 |
|
| 2003 |
Walters DK, French JD, Arendt BK, Jelinek DF. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex. Oncogene. 22: 3598-607. PMID 12789268 DOI: 10.1038/Sj.Onc.1206512 |
0.354 |
|
| 2003 |
Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. British Journal of Haematology. 121: 287-95. PMID 12694251 DOI: 10.1046/J.1365-2141.2003.04265.X |
0.397 |
|
| 2003 |
Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Molecular Cancer Research : McR. 1: 346-61. PMID 12651908 |
0.4 |
|
| 2003 |
Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood. 101: 3778-83. PMID 12560229 DOI: 10.1182/Blood-2002-08-2641 |
0.378 |
|
| 2003 |
Thomas CW, Egan LJ, Myhre GM, Tschumper RC, Rasmussen DL, Sreekumar R, Charlton MR, Jelinek DF, Sandborn WJ. Exploring the mechanism of action of azathioprine (AZA) in IBD: Expression profiling reveals an inhibitory effect of AZA on inflammatory cytokine gene expression in activated T cells Gastroenterology. 124: A335. DOI: 10.1016/S0016-5085(03)81687-6 |
0.381 |
|
| 2003 |
Thomas CW, Egan LJ, Myhre GM, Tschumper RC, Rasmussen DL, Raghavakaimal S, Charlton MR, Jelinek DF, Sandborn WJ. AZATHIOPRINE DOWNREGULATES TRAIL EXPRESSION IN A T CELL LINE AND IN NORMAL HUMAN PERIPHERAL BLOOD T CELLS American Journal of Gastroenterology. 98: S256. DOI: 10.1016/S0002-9270(03)01543-0 |
0.383 |
|
| 2002 |
Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Chronic lymphocytic leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 193-213. PMID 12446424 DOI: 10.1182/Asheducation-2002.1.193 |
0.398 |
|
| 2002 |
Arendt B, Velazquez-Dones A, Tschumper R, Howell K, Ansell S, Witzig T, Jelinek D. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells Leukemia. 16: 2142-2147. PMID 12357369 DOI: 10.1038/Sj.Leu.2402714 |
0.393 |
|
| 2002 |
Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 100: 2973-9. PMID 12351410 DOI: 10.1182/Blood-2002-02-0558 |
0.58 |
|
| 2002 |
Kay NE, Jelinek DF. B-CLL: is the enigma of disease heterogeneity about to be revealed? Blood. 100: 1110-1. PMID 12149185 DOI: 10.1182/Blood.V100.4.1110B |
0.422 |
|
| 2002 |
French JD, Tschumper RC, Jelinek DF. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia. 16: 1189-96. PMID 12040452 DOI: 10.1038/Sj.Leu.2402516 |
0.356 |
|
| 2002 |
Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules Leukemia. 16: 911-919. PMID 11986954 DOI: 10.1038/Sj.Leu.2402467 |
0.491 |
|
| 2002 |
Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 99: 67-74. PMID 11756154 DOI: 10.1182/Blood.V99.1.67 |
0.37 |
|
| 2001 |
Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, Stenson MJ, Witzig TE, Tefferi A, Kay NE. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia British Journal of Haematology. 115: 854-861. PMID 11843819 DOI: 10.1046/J.1365-2141.2001.03149.X |
0.516 |
|
| 2001 |
Kay NE, Jelinek DF, Peterson L. Angiogenesis in B-chronic lymphocytic leukemia. Leukemia Research. 25: 709-10. PMID 11397477 DOI: 10.1016/S0145-2126(01)00002-9 |
0.406 |
|
| 2001 |
Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 720-6. PMID 11157023 DOI: 10.1200/Jco.2001.19.3.720 |
0.464 |
|
| 2000 |
French JD, Tschumper RC, Jelinek DF. Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growth. Acta Oncologica (Stockholm, Sweden). 39: 777-81. PMID 11145432 DOI: 10.1080/028418600750063497 |
0.371 |
|
| 2000 |
Jelinek DF. Regulation of B lymphocyte differentiation. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 84: 375-85; quiz 385-7. PMID 10795645 DOI: 10.1016/S1081-1206(10)62267-3 |
0.412 |
|
| 2000 |
Jelinek DF. Mechanisms of myeloma cell growth control. Hematology/Oncology Clinics of North America. 13: 1145-57. PMID 10626141 DOI: 10.1016/S0889-8588(05)70117-9 |
0.411 |
|
| 1998 |
Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression. The Journal of Biological Chemistry. 273: 11799-805. PMID 9565604 DOI: 10.1074/Jbc.273.19.11799 |
0.367 |
|
| 1997 |
Jelinek DF, Arora T. Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness. Current Topics in Microbiology and Immunology. 224: 261-8. PMID 9308250 DOI: 10.1007/978-3-642-60801-8_27 |
0.398 |
|
| 1997 |
Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. The Journal of Clinical Investigation. 99: 447-56. PMID 9022078 DOI: 10.1172/Jci119179 |
0.32 |
|
| 1995 |
Lust JA, Jelinek DF, Donovan KA, Frederick LA, Huntley BK, Braaten JK, Maihle NJ. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). Current Topics in Microbiology and Immunology. 194: 199-206. PMID 7895493 DOI: 10.1007/978-3-642-79275-5_24 |
0.36 |
|
| 1995 |
Westendorf JJ, Ahmann GJ, Lust JA, Tschumper RC, Greipp PR, Katzmann JA, Jelinek DF. Molecular and biological role of CD40 in multiple myeloma. Current Topics in Microbiology and Immunology. 194: 63-72. PMID 7534674 DOI: 10.1007/978-3-642-79275-5_9 |
0.305 |
|
| 1995 |
Westendorf J, Lammert J, Jelinek D. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines Blood. 85: 3566-3576. DOI: 10.1182/Blood.V85.12.3566.Bloodjournal85123566 |
0.46 |
|
| 1994 |
Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cellular Immunology. 156: 493-507. PMID 7517796 DOI: 10.1006/Cimm.1994.1193 |
0.473 |
|
| 1991 |
Splawski JB, Jelinek DF, Lipsky PE. Delineation of the functional capacity of human neonatal lymphocytes. The Journal of Clinical Investigation. 87: 545-53. PMID 1825090 DOI: 10.1172/Jci115029 |
0.457 |
|
| 1990 |
Pisetsky DS, Jelinek DF, McAnally LM, Reich CF, Lipsky PE. In vitro autoantibody production by normal adult and cord blood B cells. The Journal of Clinical Investigation. 85: 899-903. PMID 2138166 DOI: 10.1172/Jci114517 |
0.463 |
|
| 1989 |
Lipsky PE, Hirohata S, Jelinek DF, McAnally L, Splawski JB. Regulation of human B lymphocyte responsiveness. Scandinavian Journal of Rheumatology. Supplement. 76: 229-35. PMID 3075079 DOI: 10.3109/03009748809102973 |
0.486 |
|
| 1987 |
Jelinek DF, Lipsky PE. Regulation of human B lymphocyte activation, proliferation, and differentiation. Advances in Immunology. 40: 1-59. PMID 3109220 DOI: 10.1016/S0065-2776(08)60237-0 |
0.309 |
|
| 1986 |
Jelinek DF, Splawski JB, Lipsky PE. The roles of interleukin 2 and interferon-gamma in human B cell activation, growth and differentiation. European Journal of Immunology. 16: 925-32. PMID 3091378 DOI: 10.1002/Eji.1830160809 |
0.429 |
|
| 1985 |
Jelinek DF, Thompson PA, Lipsky PE. Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells. The Journal of Clinical Investigation. 75: 1339-49. PMID 3872889 DOI: 10.1172/Jci111835 |
0.505 |
|
| Show low-probability matches. |